VBIV(Delisted)
VBI Vaccines·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
Low Cash Short-term Debt Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VBIV
Vbi Vaccines Inc.
A commercial stage biopharmaceutical company that developing vaccines for significant infectious diseases
160 Second Street, Floor 3, Cambridge, MA 02142
--
VBI Vaccines Inc. was incorporated on April 9, 1965 under the laws of British Columbia. The company is an immunology-driven commercial-stage biopharmaceutical company pursuing the prevention and treatment of diseases. Through its innovative approach to virus-like particles, including proprietary coated VLP platform technology and proprietary mRNA-launched eVLP platform technology, VBI develops candidate vaccines that mimic the natural presentation of viruses and are designed to stimulate the innate power of the human immune system. VBI is dedicated to targeting and overcoming major infectious diseases, including hepatitis B, new Covid-19 and coronavirus, cytomegalovirus, and aggressive cancers including glioblastoma.
Company Financials
EPS
VBIV has released its 2024 Q1 earnings. EPS was reported at -0.55, versus the expected -0.53, missing expectations. The chart below visualizes how VBIV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VBIV has released its 2024 Q1 earnings report, with revenue of 1.21M, reflecting a YoY change of 150.31%, and net profit of -17.90M, showing a YoY change of 35.50%. The Sankey diagram below clearly presents VBIV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
